Featured

Soleno Therapeutics Announces Presentations on VYKAT™ XR for Prader-Willi Syndrome at ENDO 2025

July 2, 2025

Soleno Therapeutics announced that two presentations featuring data on VYKAT™ XR (diazoxide choline) extended-release tablets for the treatment of hyp...

Clinical trial Updates

Soleno Therapeutics Announces Presentations on VYKAT™ XR for Prader-Willi Syndrome at ENDO 2025

Soleno Therapeutics announced that two presentations featuring data on VYKAT™ XR (diazoxide choline) extended-release tablets for the treatment of hyp...

OS Therapies Announces Positive Phase 2b Data for OST-HER2 in Osteosarcoma

OS Therapies announced positive one-year event-free survival (EFS), overall survival, and safety data from its Phase 2b trial of OST-HER2 in patients ...

Clene Provides Regulatory Update on CNM-Au8 for ALS and MS

Clene, Inc. announced a positive Type C meeting with the FDA regarding its statistical analysis plan for CNM-Au8 in ALS patients. The FDA provided co...

Klotho Neurosciences Advances Manufacturing of ALS Gene Therapy KLTO-202

Klotho Neurosciences announced it is progressing with manufacturing and process development for KLTO-202, a gene therapy targeting amyotrophic lateral...

MeCo Score: A Novel Biomarker for Predicting Response to Antifibrotic Therapy in Breast Cancer

A multinational study published in the journal *Cancers* reveals that the MeCo Score, a novel biomarker, quantifies mechanical conditioning in breast ...

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Pain Treatment

Artelo Biosciences announced positive results from its first-in-human Phase 1 study of ART26.12, a novel, orally administered FABP5 inhibitor for pers...

Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine

Moderna announced positive Phase 3 results for its seasonal influenza vaccine candidate, mRNA-1010. The study demonstrated a 26.6% higher relative va...

Edgewise Therapeutics Announces Positive Sevasemten Results for Becker and Duchenne Muscular Dystrophy

Edgewise Therapeutics reported positive results from its sevasemten program for Becker and Duchenne muscular dystrophies. In Becker MD, open-label da...

DBV Technologies Begins Phase 3 Safety Study for Viaskin Peanut Patch in Peanut-Allergic Toddlers

DBV Technologies announced the first subject has been screened in its COMFORT Toddlers study, a Phase 3 supplemental safety study evaluating the Viask...

Aldeyra Therapeutics Receives FDA Special Protocol Assessment for ADX-2191 in Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics announced that it received a Special Protocol Assessment Agreement from the FDA for ADX-2191, a novel formulation of methotrexate...

GeneDx's SeqFirst Study Shows Rapid Genomic Testing Significantly Improves Pediatric Diagnosis

GeneDx announced data from the SeqFirst study, conducted in partnership with Seattle Children's, demonstrating the effectiveness of rapid exome sequen...

Oncotelic Therapeutics Announces Publication Showing TGFB2 Methylation as Positive Prognostic Marker in Pancreatic Cancer

Oncotelic Therapeutics announced the publication of a study in the *International Journal of Molecular Sciences* showing that TGFB2 gene methylation i...

ONCare Alliance and Exigent Research Launch Outpatient Bispecifics Cancer Treatment Program

ONCare Alliance and Exigent Research have launched a groundbreaking outpatient bispecific antibody program for cancer treatment. This program, develo...

Alafair Biosciences Initiates Multi-Center Study on VersaWrap® for Achilles Tendon Repair

Alafair Biosciences announced the enrollment of the first patient in a multi-center study evaluating VersaWrap®, a bioresorbable tendon protector, for...

Vial Initiates Phase 1 Trial of Subcutaneous Half-Life Extended Anti-TL1A Antibody for IBD

Vial, a clinical-stage biotechnology company, announced the first-in-human dosing of its novel, subcutaneous, half-life extended monoclonal antibody t...

Enterra Medical Initiates NAVIGATE Study for Gastric Electrical Stimulation (GES) in Chronic Nausea

Enterra Medical has launched the NAVIGATE study to evaluate the safety and effectiveness of Gastric Electrical Stimulation (GES) for treating chronic ...

Immunic Reports Positive Long-Term Data for Vidofludimus Calcium in MS

Immunic, Inc. announced positive long-term open-label extension (OLE) data from its Phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) in relaps...

Qlaris Bio to Present New Data on QLS-111 for Glaucoma at World Glaucoma Congress

Qlaris Bio announced that new clinical and preclinical data on its lead investigational compound, QLS-111, will be presented at the 2025 World Glaucom...

Novo Nordisk Advances Amycretin, an Obesity Medication, to Phase 3 Clinical Development

Novo Nordisk announced positive results from two early-phase clinical trials of amycretin, a novel investigational obesity treatment, published in The...

Compass Pathways' COMP360 Psilocybin Shows Positive Phase 3 Results for Treatment-Resistant Depression

Compass Pathways announced positive top-line results from its Phase 3 COMP005 trial evaluating COMP360, a synthetic psilocybin formulation, for treatm...

Soleno Therapeutics Announces Presentations on Diazoxide Choline for Prader-Willi Syndrome at International Conference

Soleno Therapeutics announced multiple presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference. The presentations wi...

Poxel SA Highlights Imeglimin's Potential at ADA 2025

Poxel SA announced that five presentations on the therapeutic potential of Imeglimin (TWYMEEG®), a first-in-class treatment for type 2 diabetes, will ...

UCB Presents Thymidine Kinase 2 Deficiency (TK2d) Research at UMDF 2025 Conference

UCB presented new research on thymidine kinase 2 deficiency (TK2d) at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference. The present...

Indivior Presents Data on SUBLOCADE for Opioid Use Disorder in High Fentanyl Users

Indivior presented new data at the College on Problems of Drug Dependence (CPDD) meeting, showing that a higher dose (300mg) of SUBLOCADE (buprenorphi...

Telomir Pharmaceuticals' Telomir-1 Shows Promise in Preventing Cellular Aging in Progeria

Telomir Pharmaceuticals announced preclinical data showing its lead candidate, Telomir-1, prevented cellular aging in human progeria cell lines. Telo...

Tevogen Updates Development of AI-Powered EBV-Specific T Cell Therapy

Tevogen Bio Holdings Inc. announced an update on its development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-associat...

Spyre Therapeutics to Report Phase 1 Interim Results for SPY002 Anti-TL1A Antibody

Spyre Therapeutics announced that it will report interim results from Phase 1 healthy volunteer trials for its SPY002 program, a novel half-life exten...

AbbVie's VERONA Trial for Higher-Risk Myelodysplastic Syndromes Misses Primary Endpoint

AbbVie announced that the Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk myelodysplastic s...

Ocugen Announces FDA Clearance for Phase 2/3 Trial of OCU410ST for Stargardt Disease

Ocugen, Inc. announced that the U.S. FDA has cleared an Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory clinical...

Lyell Immunopharma Announces Positive Clinical Data for LYL314 in Large B-cell Lymphoma

Lyell Immunopharma announced positive Phase 1/2 clinical trial data for LYL314, a dual-targeting CD19/CD20 CAR T-cell therapy, in patients with relaps...

Breathe BioMedical Expands Multi-Center Breast Cancer Breath Test Trial

Breathe BioMedical announced the launch of the second site in its multi-center observational study evaluating a breath test for early breast cancer de...

Spyre Therapeutics Announces Positive Phase 1 Results for Anti-TL1A Antibody Programs and Phase 2 Clinical Development Plans

Spyre Therapeutics announced positive interim Phase 1 results for SPY002 and SPY072, two investigational, extended half-life monoclonal antibodies tar...

Hengrui and Kailera Present Clinical Data for HRS9531 and HRS-7535 at ADA 2025

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics announced the presentation of six abstracts at the American Diabetes Association's 85th Scien...

KalVista Pharmaceuticals Presents Positive Data on Sebetralstat for On-Demand HAE Treatment

KalVista Pharmaceuticals announced positive data from the KONFIDENT-S trial at the EAACI Congress 2025, showcasing sebetralstat's efficacy as an oral,...

Novo Nordisk Advances Amycretin for Weight Management to Phase 3

Novo Nordisk announced its advancement of both subcutaneous and oral amycretin into phase 3 clinical development for weight management. This decision ...

ITM to Present COMPETE Trial Data at SNMMI 2025 Annual Meeting

ITM Isotope Technologies Munich SE announced that it will present further analysis from its completed Phase 3 COMPETE trial at the SNMMI 2025 annual m...

Promising Antileukemic Activity of Bleximenib in Combination Therapy for Acute Myeloid Leukemia

Johnson & Johnson announced positive Phase 1b data for bleximenib, a menin inhibitor, in combination with venetoclax and azacitidine for acute myeloid...

Schrödinger Reports Encouraging Phase 1 Data for SGR-1505 in Relapsed/Refractory B-cell Malignancies

Schrödinger announced positive initial clinical data from a Phase 1 study of SGR-1505, an oral MALT1 inhibitor, in patients with relapsed/refractory B...

BIMZELX® (bimekizumab) Shows Lasting Efficacy in Psoriatic Arthritis and Axial Spondyloarthritis After Three Years

UCB announced three-year data from Phase 3 trials and open-label extensions showing sustained efficacy of BIMZELX® (bimekizumab) in treating adults wi...

Vaxart's Second-Generation Norovirus Vaccine Shows Significantly Increased Antibody Responses in Phase 1 Trial

Vaxart, Inc. announced positive topline results from a Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine. The trial...

MolecuLight Imaging Improves Deep Sternal Wound Infection Outcomes and Reduces Costs in Taiwan Study

A clinical study published in the Journal of Wound Care demonstrates that MolecuLight's i:X® device significantly improves outcomes for deep sternal w...

Kazia Therapeutics Announces Preclinical Data on Paxalisib for Triple-Negative Breast Cancer

Kazia Therapeutics announced the publication of preclinical research in Molecular Cancer Therapeutics demonstrating paxalisib's potential to overcome ...

BioInvent Announces Positive Phase 1 Data for BI-1206 in Combination with Pembrolizumab in Solid Tumors

BioInvent International AB announced positive Phase 1 data for its drug candidate BI-1206, used in combination with Merck's KEYTRUDA (pembrolizumab), ...

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

Travere Therapeutics announced it will present new data on FILSPARI (sparsentan) at the International Podocyte Conference. Data from the Phase 2 SPAR...

Harmony Biosciences Presents Preclinical Data for BP1.15205, a Potential Best-in-Class OX2R Agonist for Narcolepsy

Harmony Biosciences announced positive preclinical data for BP1.15205, a novel orexin 2 receptor (OX2R) agonist, demonstrating significant wake-promot...

Masimo SedLine® Improves Pediatric Anesthesia Outcomes

A randomized clinical trial published in JAMA Pediatrics demonstrates that EEG-guided anesthesia using Masimo SedLine® Brain Function Monitoring signi...

Envoy Medical's Pivotal Trial for Acclaim® Cochlear Implant Shows Positive One-Month Follow-Up Results

Envoy Medical announced positive one-month follow-up results from the first stage of its pivotal clinical trial for the fully implanted Acclaim® Cochl...

Novo Nordisk to Present New Data on Semaglutide, CagriSema, and Amycretin at ADA 2025

Novo Nordisk announced it will present new data at the American Diabetes Association (ADA) 85th Scientific Sessions in June 2025. This includes Phase...

Vergent Bioscience's Abenacianine Improves Lung Cancer Tumor Visualization in Phase 2B Trial

Vergent Bioscience announced positive Phase 2B VISUALIZE trial results for abenacianine (VGT-309), a tumor-targeted fluorescent imaging agent. The tr...

Hologic Presents New Data on Breast Cancer Index® Test at ASCO 2025

Hologic announced new data on the Breast Cancer Index® (BCI®) test, to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Me...

Servier to Present Updates on IDH-Mutated Cancer Research at ASCO 2025

Servier announced it will present updates from its research programs at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Presenta...

Tiziana Life Sciences Highlights Intranasal Foralumab for Moderate Alzheimer's Disease

Tiziana Life Sciences announced positive advancements in moderate Alzheimer's disease treatment using intranasal foralumab, a fully human anti-CD3 mon...

Positive Updated Results for Avutometinib Plus Defactinib in Frontline Metastatic Pancreatic Cancer

Verastem Oncology announced positive updated results from the RAMP 205 Phase 1/2 trial evaluating the combination of avutometinib and defactinib with ...

CytoSorbents Therapy Reduces Bleeding in Urgent CABG Patients on Ticagrelor

CytoSorbents Corporation announced results from a real-world data analysis presented at EuroPCR 2025, showing that its CytoSorbents therapy significan...

EMD Serono Presents Oncology Data at ASCO 2025

EMD Serono announced the presentation of new oncology data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Key highlights in...

Daiichi Sankyo Presents Practice-Changing ENHERTU Data at ASCO 2025

Daiichi Sankyo announced positive late-breaking data from two phase 3 trials, DESTINY-Breast09 and DESTINY-Gastric04, highlighting ENHERTU (trastuzuma...

ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy

ImCheck Therapeutics announced positive interim data from its Phase I/II EVICTION study evaluating ICT01, a γ9δ2 T-cell activator, in combination with...

Alligator Bioscience Presents Positive Biomarker Data for Mitazalimab in Pancreatic Cancer at ASCO 2025

Alligator Bioscience announced the presentation of biomarker data from its OPTIMIZE-1 clinical trial at the 2025 ASCO Annual Meeting. OPTIMIZE-1 is a ...

MiraDx's MicroRNA-based Platform Predicts Cancer Treatment Outcomes

MiraDx announced two studies to be presented at ASCO 2025, showcasing their mirSNP platform's ability to predict treatment-related toxicity and respon...

HUTCHMED to Present Clinical Data at 2025 ASCO Annual Meeting

HUTCHMED announced that new data from several clinical studies of its compounds, including savolitinib, ranosidenib, fruquintinib, and surufatinib, wi...

SystImmune to Present izalontamab brengitecan (iza-bren) Data at ASCO 2025

SystImmune, Inc. announced that data from clinical trials evaluating izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific antibody-drug conjuga...

Bicara Therapeutics Announces Positive Interim Data for Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics announced updated interim data from a Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab for first-lin...

Biodesix to Present VeriStrat® Test Data at ASCO 2025

Biodesix announced new data from the INSIGHT study (NCT03289780) on the VeriStrat® Host Immune Classifier (HIC) test, to be presented at the 2025 ASCO...

Actuate Therapeutics Announces Positive Phase 2 Elraglusib Data in Metastatic Pancreatic Cancer

Actuate Therapeutics announced positive topline Phase 2 data for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metasta...

Adagene Announces Positive Updated Data for Muzastotug (ADG126) in Combination with Pembrolizumab for Colorectal Cancer at ASCO

Adagene announced updated Phase 1b/2 data for its anti-CTLA-4 antibody, Muzastotug (ADG126), in combination with pembrolizumab, in patients with micro...

Linvoseltamab Combination Therapy Shows Promising Results in Multiple Myeloma

Regeneron Pharmaceuticals announced positive initial results from the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with carfilzom...

Legend Biotech Presents New Data on CARVYKTI® and Pipeline Candidates at ASCO, EHA, and ASGCT

Legend Biotech announced new data on CARVYKTI® (ciltacabtagene autoleucel), a CAR-T therapy for multiple myeloma, to be presented at ASCO and EHA. Lo...

Genmab to Present Late-Stage Oncology Data at ASCO 2025

Genmab announced it will present new data at the 2025 ASCO Annual Meeting, focusing on its late-stage oncology portfolio. Key highlights include the ...

Bicycle Therapeutics Announces Positive Clinical Trial Results for Zelenectide Pevedotin at ASCO 2025

Bicycle Therapeutics announced the presentation of two abstracts at the 2025 ASCO Annual Meeting, showcasing preliminary results from their Phase 1/2 ...

Avidicure to Present Preclinical Data on TROP2-Targeting Antibody at ASCO 2025

Avidicure announced it will present preclinical data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlights AVC...

Columvi Extends Overall Survival in Relapsed/Refractory DLBCL Patients: Two-Year Follow-up Data

Roche announced two-year follow-up data from the Phase III STARGLO study, showing a 40% improvement in overall survival (OS) for patients with relapse...

Autobahn Therapeutics Presents Positive Phase 1 Results for ABX-002 at ASCP Annual Meeting

Autobahn Therapeutics announced positive Phase 1 clinical trial results for ABX-002, a novel thyroid hormone beta receptor (TRβ) selective agonist, at...

Exact Sciences Highlights Cancer Detection Innovations at ASCO 2025

Exact Sciences announced the presentation of ten abstracts at the 2025 ASCO Annual Meeting, showcasing new data on its Oncodetect MRD test, multi-canc...

Hydronidone Shows Significant Fibrosis Regression in Phase 3 Trial for CHB-Associated Liver Fibrosis

Gyre Therapeutics announced positive Phase 3 results for Hydronidone (F351) in treating liver fibrosis associated with chronic hepatitis B (CHB) in Ch...

Guardant Health to Present Liquid Biopsy Data at ASCO 2025

Guardant Health announced that it and its collaborators will present data from over 19 studies at the 2025 ASCO Annual Meeting. These studies highlig...

Kelun-Biotech Presents Positive Clinical Trial Data at ASCO 2025

Kelun-Biotech announced the publication of six abstracts from its clinical studies at the 2025 ASCO Annual Meeting. The abstracts highlight data on t...

ImPact Biotech to Present ENLIGHTED Study Interim Analysis at ASCO 2025

ImPact Biotech announced that it will present interim data from its Phase 3 ENLIGHTED study of Padeliporfin VTP in patients with low-grade upper tract...

Lilly Announces ASCO 2025 Presentations on Oncology Pipeline

Eli Lilly and Company announced that data from several investigational oncology therapies will be presented at the 2025 American Society of Clinical O...

Astria Therapeutics to Present Navenibart Data at C1 Inhibitor Deficiency and Angioedema Workshop

Astria Therapeutics announced that it will present safety and efficacy data from Phase 1a and 1b/2 clinical trials of navenibart, a monoclonal antibod...

Boehringer Ingelheim to Present Early Clinical Data on SIRPα Inhibitors at ASCO 2025

Boehringer Ingelheim announced that it will present new clinical data from two early-stage trials investigating SIRPα inhibitors at the 2025 ASCO Annu...

Petosemtamab Plus Pembrolizumab Shows Strong Efficacy in Head and Neck Cancer

Merus N.V. announced positive interim data from a Phase 2 trial of petosemtamab in combination with pembrolizumab for first-line treatment of PD-L1+ r...

XTANDI Shows Long-Term Overall Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer

Five-year follow-up data from the Phase 3 ARCHES trial (NCT02677896) demonstrates that XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) s...

Rakuten Medical Announces Phase 3 Trial Progress for ASP-1929 Photoimmunotherapy at ASCO 2025

Rakuten Medical announced that it will present a Trial in Progress poster at the 2025 ASCO Annual Meeting, showcasing its global Phase 3 clinical tria...

Positive Phase II Results for CARsgen's Satri-cel in Advanced Gastric Cancer

CARsgen Therapeutics announced positive results from a Phase II clinical trial (CT041-ST-01, NCT04581473) of satricabtagene autoleucel (satri-cel), a ...

Vistagen to Present Research on Itruvone and Fasedienol at ASCP Conference

Vistagen, a clinical-stage biopharmaceutical company, announced it will present at the 2025 American Society of Clinical Psychopharmacology (ASCP) Con...

Mythic Therapeutics Presents Positive Phase 1 Data for MYTX-011 in NSCLC

Mythic Therapeutics announced positive efficacy data from the Phase 1 KisMET-01 study of MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in ...

Pfizer to Present Phase 1 Data on MesoC2 ADC at ASCO 2025

Nona Biosciences announced that its collaborator, Pfizer, will present the Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666), a first-in-c...

Bristol Myers Squibb to Present Oncology Data at ASCO 2025

Bristol Myers Squibb announced the presentation of data from over 80 studies at the 2025 ASCO Annual Meeting. The data covers more than 20 cancer typ...

Updated Elacestrant Data Highlights Combinability in Metastatic Breast Cancer

Menarini Group presented updated data from the Phase 1b/2 ELEVATE study at ASCO 2025, showcasing the efficacy and safety of elacestrant (ORSERDU®) in ...

Taiho Oncology Presents Positive Data at ASCO 2025 Annual Meeting

Taiho Oncology announced new data to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Highlights include data on...

Merus' Bispecific Antibody Shows Promising Results in Head and Neck Cancer

Merus announced positive Phase II data for its bispecific antibody petosemtamab in combination with Keytruda (pembrolizumab) for first-line treatment ...

RWJBarnabas Health and Rutgers Cancer Institute to Present Cancer Research at ASCO 2025

RWJBarnabas Health and Rutgers Cancer Institute will present 45 abstracts and presentations at the 2025 ASCO Annual Meeting. Research highlights incl...

Boehringer Ingelheim to Present Early Clinical Data on SIRPα Inhibitors at ASCO 2025

Boehringer Ingelheim will present data from two early-stage clinical trials investigating their SIRPα inhibitors, BI 765063 and BI 770371, at the 2025...

Ascentage Pharma's Lisaftoclax Shows Promise in Venetoclax-Refractory Patients; ASCO 2025 Presentation

Ascentage Pharma announced positive clinical data for lisaftoclax, a Bcl-2 inhibitor, and alrizomadlin, an MDM2-p53 inhibitor. Data from a Phase 1b/2...

Ziftomenib Shows Promise in Treating Relapsed/Refractory NPM1-Mutant AML

Kura Oncology and Kyowa Kirin announced positive pivotal data for ziftomenib, an oral menin inhibitor, in patients with relapsed/refractory (R/R) NPM1...

Exelixis Presents Encouraging Zanzalintinib Combination Therapy Results for Advanced Kidney Cancer at ASCO 2025

Exelixis announced positive results from the Phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with immune checkpoint inhibitors fo...

Immix Biopharma's NXC-201 Shows Promising Results for Relapsed/Refractory AL Amyloidosis

Immix Biopharma announced positive results from its Phase 1/2 NEXICART-2 clinical trial of NXC-201, a sterically-optimized BCMA-targeted CAR-T cell th...

Improved Cardiac Surgery Outcomes with Active Chest Tube Clearance

ClearFlow, Inc. announced positive clinical trial results showing that its PleuraFlow Active Clearance Technology (ACT) System significantly improves ...

Avalyn Pharma Presents Positive Clinical Data for Inhaled Pulmonary Fibrosis Treatments at ATS 2025

Avalyn Pharma showcased positive clinical data for its lead programs, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), at the American Thorac...

First-Ever Combined Implantation of MOTUS Device and TOPS™ System for Lumbar Spinal Degeneration

Drs. Lanman and Ament performed the first known combined implantation of the MOTUS total joint replacement device and the TOPS™ System at adjacent lum...

Home/KnloSights/clinical trial updates